Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging phase 2 study of dapirolizumab pegol in moderately to severely active systemic lupus erythematosus
2015-004457-40Phase 2Completed
- Sponsor
- UCB
- Start
- Jun 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapirolizumab pegol in systemic lupus erythematosus (SLE) (4 arms), sponsored by UCB. Primary endpoint: Percentage of subjects with BICLA response across dapirolizumab pegol dose groups at Week 24. Started Jun 2016; status: completed.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2015-004457-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004457-40.